Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 5
2010 14
2011 16
2012 30
2013 38
2014 31
2015 21
2016 25
2017 25
2018 20
2019 22
2020 12
2021 11
2022 9
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Results by year

Filters applied: . Clear all
Page 1
GDC-0941 and CXCL8 (3-72) K11R/G31P combination therapy confers enhanced efficacy against breast cancer.
Li X, Zhang Y, Walana W, Zhao F, Li F, Luo F. Li X, et al. Future Oncol. 2020 May;16(14):911-921. doi: 10.2217/fon-2020-0035. Epub 2020 Apr 14. Future Oncol. 2020. PMID: 32285685
Aim: Herein is presented the combined effect of PI3K inhibitor (GDC-0941) and CXCR1/2 analogue (G31P) in breast cancer. Materials & methods: Breast cancer cell lines and xenograft model were employed to test the efficacy of the combination therapy. Results: G …
Aim: Herein is presented the combined effect of PI3K inhibitor (GDC-0941) and CXCR1/2 analogue (G31P) in breast cancer. Materi …
GDC-0941 activates integrin linked kinase (ILK) expression to cause resistance to GDC-0941 in breast cancer by the tumor necrosis factor (TNF)-alpha signaling pathway.
Chen H, Cheng M, Gao P, Zhang X, Li G, Wang L, Qin L, Li H. Chen H, et al. Bioengineered. 2022 Apr;13(4):10944-10955. doi: 10.1080/21655979.2022.2066758. Bioengineered. 2022. PMID: 35477364 Free PMC article.
However, certain breast cancer cells are insensitive to GDC-0941. Hence, the mechanism of GDC-0941 in breast cancer resistance was investigated in this study. ...Taken together, GDC-0941 increased ILK level by upregulating TNF-alpha, thus …
However, certain breast cancer cells are insensitive to GDC-0941. Hence, the mechanism of GDC-0941 in breast can …
GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death.
Enzenmüller S, Gonzalez P, Karpel-Massler G, Debatin KM, Fulda S. Enzenmüller S, et al. Cancer Lett. 2013 Feb 1;329(1):27-36. doi: 10.1016/j.canlet.2012.09.007. Epub 2012 Sep 18. Cancer Lett. 2013. PMID: 23000516
Also, GDC-0941 triggers a time-dependent increase of the lysosomal compartment in a TFEB-dependent manner, since knockdown of TFEB significantly reduces this GDC-0941-stimulated lysosomal enhancement. ...Addition of the cathepsin B inhibitor CA-074me r …
Also, GDC-0941 triggers a time-dependent increase of the lysosomal compartment in a TFEB-dependent manner, since knockdown of …
GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1alpha (HIF-1alpha) pathways.
Burrows N, Babur M, Resch J, Ridsdale S, Mejin M, Rowling EJ, Brabant G, Williams KJ. Burrows N, et al. J Clin Endocrinol Metab. 2011 Dec;96(12):E1934-43. doi: 10.1210/jc.2011-1426. Epub 2011 Oct 12. J Clin Endocrinol Metab. 2011. PMID: 21994956
Antiproliferative effects of GDC-0941 were more pronounced in PTEN mutant compared with PTEN-restored cells (P < 0.05). ...DnHIF expression and GDC-0941 reduced FTC tumor growth and metastatic lung colonization (P < 0.05). ...

Antiproliferative effects of GDC-0941 were more pronounced in PTEN mutant compared with PTEN-restored cells (P < 0.05). ...

…
GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.
Zheng L, Yang W, Zhang C, Ding WJ, Zhu H, Lin NM, Wu HH, He QJ, Yang B. Zheng L, et al. Cancer Lett. 2011 Oct 1;309(1):27-36. doi: 10.1016/j.canlet.2011.05.011. Epub 2011 Jun 12. Cancer Lett. 2011. PMID: 21664043
The present study showed that GDC-0941 potently sensitized breast cancer to ABT-737 in vitro and in vivo. ...Furthermore, the combination of GDC-0941 and ABT-737 exerted increased anti-tumor efficacy on MDA-MB-231 xenograft models. ...
The present study showed that GDC-0941 potently sensitized breast cancer to ABT-737 in vitro and in vivo. ...Furthermore, the …
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Wallin JJ, Guan J, Prior WW, Lee LB, Berry L, Belmont LD, Koeppen H, Belvin M, Friedman LS, Sampath D. Wallin JJ, et al. Clin Cancer Res. 2012 Jul 15;18(14):3901-11. doi: 10.1158/1078-0432.CCR-11-2088. Epub 2012 May 14. Clin Cancer Res. 2012. PMID: 22586300
GDC-0941 increased the rate of apoptosis in cells arrested in mitosis upon cotreatment with docetaxel. CONCLUSION: GDC-0941 augments the efficacy of docetaxel by increasing drug-induced apoptosis in breast cancer models....
GDC-0941 increased the rate of apoptosis in cells arrested in mitosis upon cotreatment with docetaxel. CONCLUSION: GDC- …
The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F, Guo H, Zhang R, Liu H, Wu L, Wu Q, Liu J, Liu T, Zhang Q. Shi F, et al. Neuroscience. 2017 Mar 27;346:298-308. doi: 10.1016/j.neuroscience.2017.01.032. Epub 2017 Jan 29. Neuroscience. 2017. PMID: 28147244
GBM is characterized by overt activity of the phosphoinositide 3-kinase (PI3K) signaling pathway. GDC-0941 is a highly specific PI3K inhibitor with promising anti-tumor activity in human solid tumors. ...The results of this study suggest that the combination of TMZ, …
GBM is characterized by overt activity of the phosphoinositide 3-kinase (PI3K) signaling pathway. GDC-0941 is a highly specifi …
The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
Ehrhardt M, Craveiro RB, Holst MI, Pietsch T, Dilloo D. Ehrhardt M, et al. Oncotarget. 2015 Jan 20;6(2):802-13. doi: 10.18632/oncotarget.2742. Oncotarget. 2015. PMID: 25596739 Free PMC article.
GDC-0941 also synergizes with the standard medulloblastoma chemotherapeutic etoposide. ...These findings provide a rational to further investigate GDC-0941 alone and in combination with standard chemotherapeutics for medulloblastoma treatment....
GDC-0941 also synergizes with the standard medulloblastoma chemotherapeutic etoposide. ...These findings provide a rational to …
EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma.
Zhou Y, Xiao D, Jiang X, Nie C. Zhou Y, et al. J Transl Med. 2023 Jan 16;21(1):28. doi: 10.1186/s12967-023-03883-4. J Transl Med. 2023. PMID: 36647156 Free PMC article.
Furthermore, CuAS has therapeutic potential for immunotherapy, and we predict that many drugs (methotrexate, NU7441, KU -0063794, GDC-0941, cabozantinib, and NVP-BEZ235) may be used in patients with high CuAS. ...
Furthermore, CuAS has therapeutic potential for immunotherapy, and we predict that many drugs (methotrexate, NU7441, KU -0063794, GDC …
PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.
Choo EF, Ng CM, Berry L, Belvin M, Lewin-Koh N, Merchant M, Salphati L. Choo EF, et al. Cancer Chemother Pharmacol. 2013 Jan;71(1):133-43. doi: 10.1007/s00280-012-1988-6. Epub 2012 Oct 7. Cancer Chemother Pharmacol. 2013. PMID: 23053270
METHODS: GDC-0973 and GDC-0941 were administered to A2058 tumor-bearing mice daily (QD) or every third day (Q3D) either as single agents or in combination. ...The estimates for psi were not significantly different from 1, suggesting an additive effect of GDC-0973 an …
METHODS: GDC-0973 and GDC-0941 were administered to A2058 tumor-bearing mice daily (QD) or every third day (Q3D) either as sin …
257 results